Overview

Effect of OC000459 on Moderate to Severe Atopic Dermatitis

Status:
Completed
Trial end date:
2016-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether OC000459 is in reducing disease severity and preventing flares in people with moderate to severe atopic dermatitis (AD).
Phase:
Phase 2
Details
Lead Sponsor:
Atopix Therapeutics, Ltd.
Treatments:
Indoleacetic Acids